Rosuvastatin in Combination With Bortezomib Promotes Osteogenesis in Myeloma Bone Disease by Inhibiting the Secretion of CCL3. [PDF]
EJHaemABSTRACT Background Myeloma bone disease (MBD) is a devastating complication of multiple myeloma (MM) and a primary cause of disability in affected patients. Its pathogenesis is driven by an imbalance in bone remodeling, largely attributed to the overexpression of C‐C motif chemokine ligand 3 (CCL3). While both bortezomib and statins have been reported
Qu F +6 more
europepmc +2 more sources
Haematologica, 2015 Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking.
Meletios A. Dimopoulos +13 more
doaj +1 more source
Characterization of bortezomib-adapted I-45 mesothelioma cells
Molecular Cancer, 2010 Background Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy.
Peddaboina Chander +5 more
doaj +1 more source
Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy [PDF]
, 2017 KSHV and EBV are gammaherpesviruses strictly linked to human cancers. Even if the majority of cancer cells harbor a latent infection, the few cells that undergo viral replication may contribute to the pathogenesis and maintenance of the virus-associated ...
Cirone, Mara +7 more
core +2 more sources
Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications [PDF]
, 2012 Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes.
Fulda, Simone +2 more
core +2 more sources
Cytokine Dynamics in Bortezomib-Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans. [PDF]
J Peripher Nerv SystABSTRACT Background and Aims Bortezomib‐induced peripheral neuropathy (BIPN) remains a common treatment side effect in patients with multiple myeloma (MM). Data from rodent models indicate a role of proinflammatory cytokines in BIPN pathophysiology, making them potential therapeutic targets.
Cebulla N +18 more
europepmc +2 more sources
Journal of Hematology & Oncology, 2018 Background Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib.
Zhihong Zheng +7 more
doaj +1 more source
Evaluation of melanin-targeted radiotherapy in combination with radiosensitizing drugs for the treatment of melanoma [PDF]
, 2014 The incidence of malignant melanoma is rising faster than that of any other cancer in the United States. An [131I]-labeled benzamide - [131I]MIP-1145 - selectively targets melanin, reduces melanoma tumor burden and increases survival in preclinical ...
Babich, John +5 more
core +1 more source
Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness [PDF]
, 2014 Muscle wasting and cachexia are important systemic manifestations of highly prevalent conditions including cancer. Inflammation, oxidative stress, autophagy, ubiquitin-proteasome system, nuclear factor (NF)-kB, and mitogen activated protein kinases (MAPK)
Bal, Elisa Dora +7 more
core +1 more source
Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells. [PDF]
, 2019 Tumor cells harboring stem-like/cancer stem cell (CSC) properties have been identified and isolated from numerous hematological and solid malignancies.
Ames, Erik +8 more
core +1 more source